Cargando…

Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis

INTRODUCTION: Comorbidities significantly influence the clinical course of idiopathic pulmonary fibrosis (IPF). However, their prognostic impact is not fully understood. We therefore aimed to determine the impact of comorbidities, as individual and as whole, on survival in IPF. METHODS: The database...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreuter, Michael, Ehlers-Tenenbaum, Svenja, Palmowski, Karin, Bruhwyler, Jacques, Oltmanns, Ute, Muley, Thomas, Heussel, Claus Peter, Warth, Arne, Kolb, Martin, Herth, Felix J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811578/ https://www.ncbi.nlm.nih.gov/pubmed/27023440 http://dx.doi.org/10.1371/journal.pone.0151425

Ejemplares similares

Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT)
por: Colombi, Davide, et al.
Publicado: (2015)

Texture analysis using proton density and T2 relaxation in patients with histological usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP)
por: Buzan, Maria T. A., et al.
Publicado: (2017)

Comorbidities and survival in patients with chronic hypersensitivity pneumonitis
por: Wälscher, Julia, et al.
Publicado: (2020)

Diagnostik granulomatöser Erkrankungen mit Lungenbefall
por: Piel, Stella, et al.
Publicado: (2017)

What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC
por: Schneider, Marc A., et al.
Publicado: (2018)

CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
por: Zhao, Jing, et al.
Publicado: (2017)

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
por: Schneider, Marc A., et al.
Publicado: (2016)

Pulmonale granulomatöse Erkrankungen und pulmonale Manifestationen systemischer Granulomatosen: Inklusive Tuberkulose und nichttuberkulöse Mykobakteriosen
por: Piel, S., et al.
Publicado: (2016)

Managing comorbidities in idiopathic pulmonary fibrosis
por: Fulton, Blair G, et al.
Publicado: (2015)

Comorbidities and Complications in Idiopathic Pulmonary Fibrosis
por: Cano-Jiménez, Esteban, et al.
Publicado: (2018)

Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
por: Weber, Rebecca, et al.
Publicado: (2018)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection
por: Trinkmann, Frederik, et al.
Publicado: (2021)

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
por: Caminati, Antonella, et al.
Publicado: (2019)

Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas
por: Rieber, Juliane, et al.
Publicado: (2015)

Successful treatment of a recurrent granulation polyp in the airways with high-dose-rate brachytherapy: a case report
por: Polke, M., et al.
Publicado: (2017)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
por: Kärkkäinen, Miia, et al.
Publicado: (2017)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
por: Oldham, Justin M., et al.
Publicado: (2017)

AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients
por: Schneider, Marc A., et al.
Publicado: (2017)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

Management of idiopathic pulmonary fibrosis: selected case reports
por: Kreuter, Michael, et al.
Publicado: (2014)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
por: Millan-Billi, Paloma, et al.
Publicado: (2018)

Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis
por: Alhamad, Esam H., et al.
Publicado: (2020)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

The therapy of idiopathic pulmonary fibrosis: what is next?
por: Somogyi, Vivien, et al.
Publicado: (2019)

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
por: Kreuter, Michael, et al.
Publicado: (2017)

Effects of comorbid chronic kidney disease on mortality in idiopathic pulmonary fibrosis patients and influence of pirfenidone
por: Jo, Yong Suk, et al.
Publicado: (2023)

Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?
por: Alfaro, Tiago M., et al.
Publicado: (2020)

Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
por: Lee, Jang Ho, et al.
Publicado: (2023)

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
por: Rahaghi, Franck, et al.
Publicado: (2021)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Predictors of pneumothorax following endoscopic valve therapy in patients with severe emphysema
por: Gompelmann, Daniela, et al.
Publicado: (2016)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management
por: van Cleemput, Johan, et al.
Publicado: (2018)

Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
por: Jovanovic, Dragana M., et al.
Publicado: (2022)

Coil therapy for patients with severe emphysema and bilateral incomplete fissures – effectiveness and complications after 1-year follow-up: a single-center experience
por: Kontogianni, Konstantina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sf87m5caaq5spshkg76s858062